TRVI Valuation
Trevi Therapeutics Inc
$
6.640
- Overview
- Forecast
- Valuation
TRVI Relative Valuation
TRVI's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TRVI is overvalued; if below, it's undervalued.
Historical Valuation
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
6.18
P/B
Median3y
2.65
Median5y
2.47
-5.74
FCF Yield
Median3y
-20.79
Median5y
-42.04
Competitors Valuation Multiple
The average P/S ratio for TRVI's competitors is 41.49, providing a benchmark for relative valuation. Trevi Therapeutics Inc Corp (TRVI) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
ABSI
Absci Corp
2.650
USD
0.00%
GDEV
GDEV Inc.
16.690
USD
+1.52%
KRRO
Korro Bio Inc
14.800
USD
+0.03%
SSBK
Southern States Bancshares Inc
34.710
USD
0.00%
JOUT
Johnson Outdoors Inc
23.610
USD
0.00%
HVT
Haverty Furniture Companies Inc
18.930
USD
+0.42%
BNED
Barnes & Noble Education Inc
10.470
USD
+2.05%
LWAY
Lifeway Foods Inc
23.270
USD
0.00%
IHRT
iHeartMedia Inc
1.140
USD
+4.59%
LOCO
El Pollo Loco Holdings Inc
9.060
USD
+1.00%
FAQ
Is Trevi Therapeutics Inc (TRVI) currently overvalued or undervalued?
Trevi Therapeutics Inc (TRVI) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 0.00. The fair price of Trevi Therapeutics Inc (TRVI) is between to according to relative valuation methord.
What is Trevi Therapeutics Inc (TRVI) fair value?
How does TRVI's valuation metrics compare to the industry average?
What is the current P/B ratio for Trevi Therapeutics Inc (TRVI) as of May 07 2025?
What is the current FCF Yield for Trevi Therapeutics Inc (TRVI) as of May 07 2025?
What is the current Forward P/E ratio for Trevi Therapeutics Inc (TRVI) as of May 07 2025?